Christgen M

ORCID: 0000-0002-0891-7839 · 3 papers in corpus
2026
Reduced folate receptor alpha (FOLR1) protein expression in fallopian tubes from premenopausal women: implications for the FOLR1 CDx assay for mirvetuximab-soravtansine therapy.
The journal of pathology. Clinical research ·doi:10.1002/2056-4538.70091

Mirvetuximab-soravtansine (MIRV-S) is an antibody-drug conjugate targeting folate receptor alpha (FOLR1). MIRV-S is approved for the treatment of FOLR1-positive, platinum-resistant ovarian carcinoma. Patient eligibility is determined by imm…

2024
Microenvironment-induced restoration of cohesive growth associated with focal activation of P-cadherin expression in lobular breast carcinoma metastatic to the colon.
The journal of pathology. Clinical research ·doi:10.1002/2056-4538.12361

Invasive lobular carcinoma (ILC) is a special breast cancer type characterized by noncohesive growth and E-cadherin loss. Focal activation of P-cadherin expression in tumor cells that are deficient for E-cadherin occurs in a subset of ILCs.…

other 2021
Parasitic Worms in the Appendix: Incidental Finding of Concomitant Schistosomiasis in Suspected and Confirmed Endometriosis
Deutsches Arzteblatt international ·doi:10.3238/arztebl.m2021.0082